Best Supportive Care (BSC)
Phase 3
Johnson & JohnsonBest Supportive Care (BSC) is one of 10 therapeutic programs targeting Metastatic Castration-resistant Prostate Neoplasms. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
10 competitors in Metastatic Castration-Resistant Prostate Neoplasms
#DrugCompanyPhaseTrials
1Pasritamig
Johnson & JohnsonPhase 3
Jevtana
SanofiPhase 1
Erleada
Johnson & JohnsonPhase 1
Xtandi
AstellasPhase 1
Nubeqa
BayerPhase 1
Zytiga
Johnson & JohnsonPhase 1
Taxotere
AAvyxa
Phase 1
Cetrelimab
Johnson & JohnsonPhase 1
Best Supportive Care (BSC)
Johnson & JohnsonPhase 3
Jnj-101556143
Johnson & JohnsonPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Castration-resistant Prostate Neoplasms1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Best Supportive Care (BSC). EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company